Palvellatx
Wayne, US · Founded 2015 · 55 employees on LinkedIn · 2 known investors
Palvella Therapeutics is a biotechnology company developing topical treatments for rare genetic skin diseases that lack approved therapies, based on its QTORIN drug delivery platform. Its lead candidate, QTORIN rapamycin gel, is in clinical development for microcystic lymphatic malformations and other mTOR-driven dermatologic conditions.
Investors · 2
Frequently asked questions
- What does Palvellatx do?
- Palvella Therapeutics is a biotechnology company developing topical treatments for rare genetic skin diseases that lack approved therapies, based on its QTORIN drug delivery platform. Its lead candidate, QTORIN rapamycin gel, is in clinical development for microcystic lymphatic malformations and other mTOR-driven dermatologic conditions.
- Who are Palvellatx's investors?
- Palvellatx's investors include Frazier Life Sciences, Agent Capital.
- Where is Palvellatx headquartered?
- Palvellatx is headquartered in Wayne, US.